Works by Chia-Chi Lin


Results: 94
    1
    2
    3
    4

    Barriers to publishing early phase clinical trials: the oncologists' perspective.

    Published in:
    Oncologist, 2025, v. 30, n. 4, p. 1, doi. 10.1093/oncolo/oyaf042
    By:
    • Lucassen, Merel J J;
    • Bergmann, Pedro;
    • Husson, Olga;
    • Banerji, Udai;
    • Basu, Bristi;
    • Melero, Ignacio;
    • Calvo, Emiliano;
    • Cassier, Philippe A;
    • Drilon, Alexander;
    • Fong, Peter C;
    • Garralda, Elena;
    • Joshua, Anthony M;
    • Lin, Chia-Chi;
    • Lopez, Juanita;
    • Moreno, Victor;
    • Minchom, Anna;
    • Plummer, Ruth;
    • Postel-Vinay, Sophie;
    • Spreafico, Anna;
    • Shimizu, Toshio
    Publication type:
    Article
    5
    6

    Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y
    By:
    • Chia-Chi Lin;
    • Beeram, Muralidhar;
    • Rowinsky, Eric K.;
    • Takimoto, Chris H.;
    • Ng, Chee M.;
    • Geyer Jr., Charles E.;
    • Denis, Louis J.;
    • De Bono, Johann S.;
    • Hao, Desiree;
    • Tolcher, Anthony W.;
    • Rha, Sun-Young;
    • Jolivet, Jacques;
    • Patnaik, Amita
    Publication type:
    Article
    7

    Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
    By:
    • Chia-Chi Lin;
    • Calvo, Emiliano;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Sarantopoulos, John;
    • Mita, Alain C.;
    • Preston, Glenn G.;
    • Mita, Monica M.;
    • Rodon, Jordi;
    • Mays, Theresa;
    • I.-Tien Yeh;
    • O'Rourke, Pat;
    • Takimoto, Chris H.;
    • Dancey, Janet E.;
    • Chen, Helen;
    • Tolcher, Anthony W.
    Publication type:
    Article
    8
    9
    10
    11

    Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).

    Published in:
    Thyroid, 2022, v. 32, n. 9, p. 1059, doi. 10.1089/thy.2022.0061
    By:
    • Brose, Marcia S.;
    • Smit, Johannes W.A.;
    • Lin, Chia-Chi;
    • Tori, Masayuki;
    • Bowles, Daniel W.;
    • Worden, Francis;
    • Shen, Daniel Hueng-Yuan;
    • Huang, Shih-Ming;
    • Tsai, Hui-Jen;
    • Alevizaki, Maria;
    • Peeters, Robin P.;
    • Takahashi, Shunji;
    • Rumyantsev, Pavel;
    • Guan, Rongjin;
    • Babajanyan, Svetlana;
    • Ozgurdal, Kirhan;
    • Sugitani, Iwao;
    • Pitoia, Fabian;
    • Lamartina, Livia
    Publication type:
    Article
    12

    An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

    Published in:
    Thyroid, 2020, v. 30, n. 9, p. 1254, doi. 10.1089/thy.2019.0269
    By:
    • Bible, Keith C.;
    • Menefee, Michael E.;
    • Lin, Chia-Chi (Josh);
    • Millward, Michael J.;
    • Maples, William J.;
    • Goh, Boon Cher;
    • Karlin, Nina J.;
    • Kane, Madeleine A.;
    • Adkins, Douglas R.;
    • Molina, Julian R.;
    • Donehower, Ross C.;
    • Lim, Wan-Teck;
    • Flynn, Patrick J.;
    • Richardson, Ronald L.;
    • Traynor, Anne M.;
    • Rubin, Joseph;
    • LoRusso, Patricia M.;
    • Smallridge, Robert C.;
    • Burton, Jill K.;
    • Suman, Vera J.
    Publication type:
    Article
    13
    14
    15
    16
    17

    Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.

    Published in:
    2020
    By:
    • de Bono, Johann;
    • Lin, Chia-Chi;
    • Chen, Li-Tzong;
    • Corral, Jesus;
    • Michalarea, Vasiliki;
    • Rihawi, Karim;
    • Ong, Michael;
    • Lee, Jih-Hsiang;
    • Hsu, Chih-Hung;
    • Yang, James Chih-Hsin;
    • Shiah, Her-Shyong;
    • Yen, Chia-Jui;
    • Anthoney, Alan;
    • Jove, Maria;
    • Buschke, Susanne;
    • Fuertig, René;
    • Schmid, Ulrike;
    • Goeldner, Rainer-Georg;
    • Strelkowa, Natalja;
    • Huang, Dennis Chin-Lun
    Publication type:
    journal article
    18
    19

    Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

    Published in:
    2018
    By:
    • Mehra, Ranee;
    • Seiwert, Tanguy Y.;
    • Gupta, Shilpa;
    • Weiss, Jared;
    • Gluck, Iris;
    • Eder, Joseph P.;
    • Burtness, Barbara;
    • Tahara, Makoto;
    • Keam, Bhumsuk;
    • Kang, Hyunseok;
    • Muro, Kei;
    • Geva, Ravit;
    • Chung, Hyun Cheol;
    • Lin, Chia-Chi;
    • Aurora-Garg, Deepti;
    • Ray, Archana;
    • Pathiraja, Kumudu;
    • Cheng, Jonathan;
    • Chow, Laura Q. M.;
    • Haddad, Robert
    Publication type:
    journal article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34

    A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02383-5
    By:
    • Chan, Stephen L.;
    • Schuler, Martin;
    • Kang, Yoon-Koo;
    • Yen, Chia-Jui;
    • Edeline, Julien;
    • Choo, Su Pin;
    • Lin, Chia-Chi;
    • Okusaka, Takuji;
    • Weiss, Karl-Heinz;
    • Macarulla, Teresa;
    • Cattan, Stéphane;
    • Blanc, Jean-Frederic;
    • Lee, Kyung-Hun;
    • Maur, Michela;
    • Pant, Shubham;
    • Kudo, Masatoshi;
    • Assenat, Eric;
    • Zhu, Andrew X.;
    • Yau, Thomas;
    • Lim, Ho Yeong
    Publication type:
    Article
    35
    36
    37
    38
    39
    40

    Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 8, p. 1195, doi. 10.1002/cncr.34657
    By:
    • Oh, Do‐Youn;
    • Algazi, Alain;
    • Capdevila, Jaume;
    • Longo, Federico;
    • Miller, Wilson;
    • Chun Bing, Jerry Tan;
    • Bonilla, Carlos Eduardo;
    • Chung, Hyun Cheol;
    • Guren, Tormod K.;
    • Lin, Chia‐Chi;
    • Motola‐Kuba, Daniel;
    • Shah, Manisha;
    • Hadoux, Julien;
    • Yao, Lili;
    • Jin, Fan;
    • Norwood, Kevin;
    • Lebellec, Loïc
    Publication type:
    Article
    41
    42

    An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.

    Published in:
    Cancer (0008543X), 2014, v. 120, n. 7, p. 976, doi. 10.1002/cncr.28519
    By:
    • Stadler, Walter M.;
    • Vaughn, David J.;
    • Sonpavde, Guru;
    • Vogelzang, Nicholas J.;
    • Tagawa, Scott T.;
    • Petrylak, Daniel P.;
    • Rosen, Peter;
    • Lin, Chia‐Chi;
    • Mahoney, John;
    • Modi, Sanjiv;
    • Lee, Peter;
    • Ernstoff, Marc S.;
    • Su, Wu‐Chou;
    • Spira, Alexander;
    • Pilz, Korinna;
    • Vinisko, Richard;
    • Schloss, Charles;
    • Fritsch, Holger;
    • Zhao, Charles;
    • Carducci, Michael A.
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50